Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors-Reference-Cited by-同舟云学术

Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors

Published:2017-07-05 Issue:9 Volume:11 Page:1156-1171
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Kolberg Matthias¹²^ORCID,Bruun Jarle¹²,Murumägi Astrid³,Mpindi John P.³,Bergsland Christian H.¹²,Høland Maren¹²,Eilertsen Ina A.¹²,Danielsen Stine A.¹²,Kallioniemi Olli³⁴⁵,Lothe Ragnhild A.¹²

Affiliation:

1. Department of Molecular Oncology; Institute for Cancer Research; the Norwegian Radium Hospital; Oslo University Hospital; Norway

2. Centre for Cancer Biomedicine; University of Oslo; Norway

3. Institute for Molecular Medicine Finland; FIMM; University of Helsinki; Finland

4. Science for Life Laboratory; Solna Sweden

5. Department of Oncology and Pathology; Karolinska Institutet; Solna Sweden

Funder

Norges Forskningsråd

Kreftforeningen

Helse Sør-Øst RHF

Universitetet i Oslo

Stiftelsen Kristian Gerhard Jebsen

Suomen Akatemia

Syöpäjärjestöt

Sigrid Juséliuksen Säätiö

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Reference71 articles.

1. Polo-like kinase inhibitor volasertib exhibits antitumor activity and synergy with vincristine in pediatric malignancies;Abbou;Anticancer Res,2016

2. Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors;Ågesen;J Neuropathol Exp Neurol,2005

3. RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A;Ahlquist;Neoplasia,2008

4. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST);Albritton;J Clin Oncol,2006

5. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells;Ambrosini;Mol Cancer Ther,2008

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets;eBioMedicine;2023-11

2. HN1L/AP-2γ/PLK1 signaling drives tumor progression and chemotherapy resistance in esophageal squamous cell carcinoma;Cell Death & Disease;2022-12-07

3. Malignant peripheral nerve sheath tumor: models, biology, and translation;Oncogene;2022-04-07

4. High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma;Translational Oncology;2022-01

5. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors;Cancer Research;2020-10-08